Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.30 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599446 | 1.00 | CXCR2 (0.43) | CXCR2LMNAPTPRZ1PTPN2PTPN1 | |
| SCHEMBL25598661 | 1.00 | CXCR2 (0.43) | CXCR2LMNAPTPRZ1PTPN2PTPN1 | |
| SCHEMBL25602752 | 0.92 | CXCR2 (0.46) | CXCR2LMNAPTPRZ1PTPN2PTPN1 | |
| SCHEMBL25598596 | 0.92 | CXCR2 (0.46) | CXCR2LMNAPTPRZ1PTPN2PTPN1 | |
| SCHEMBL25599148 | 0.91 | CXCR2 (0.40) | CXCR2PTPN2PTPN1PTPN7KCNK2 | |
| SCHEMBL25598602 | 0.91 | CXCR2 (0.40) | CXCR2PTPN2PTPN1PTPN7KCNK2 | |
| SCHEMBL23460088 | 0.89 | CXCR2 (0.46) | CXCR2LMNAPTPRZ1KCNK2KCNK10 | |
| SCHEMBL25599181 | 0.87 | CXCR2 (0.43) | CXCR2LMNAPTPRZ1KCNK2KCNK10 | |
| SCHEMBL25598608 | 0.87 | CXCR2 (0.43) | CXCR2LMNAPTPRZ1KCNK2KCNK10 | |
| SCHEMBL23459970 | 0.86 | PTPRZ1 (0.33) | CXCR2PTPRZ1PTPN1PDE2ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113808-A1 | CFTR-MODULATING ARYLAMIDES | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | CXCR2 78/4885LMNA 2762/4885PTPRZ1 1650/4885 |
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885LMNA 3155/4885PTPRZ1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.